{
  "docId": "019de073-ace7-72fb-abe1-daa413db1006",
  "docSlug": "7bdf7da39a85a072a380631ad1d0379d",
  "documentTitle": "Cabaletta Bio | Investor Presentation Deck | 23 slides",
  "authorId": "cabaletta-bio",
  "authorName": "Cabaletta Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 23,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a bulleted list structure to summarize key clinical milestones and financial position.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ace7-72fb-abe1-daa413db1006/4",
  "deckHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006",
  "deckJsonHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006.json",
  "deckAnchorHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.04,
        "y": 0.82
      },
      "kind": "disclaimer",
      "text": "CAART – Chimeric AutoAntibody Receptor T cells; CARTA – Chimeric Antigen Receptor T cells for Autoimmunity; IND – Investigational New Drug; SLE – Systemic lupus erythematosus; RA – Rheumatoid arthritis; mPV – Mucosal pemphigus vulgaris",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06f98897-63d3-4102-a146-d2d0cc733f68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.04,
        "y": 0.86
      },
      "kind": "disclaimer",
      "text": "1. Mackensen, Andreas, et al. \"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.\" Nature Medicine (2022): 1-9. 2. Dai, Zhenyu, et al. \"Development and functional characterization of novel fully human anti-CD19 CARs for T-cell therapy.\" Journal of Cellular Physiology 236.8 (2021): 5832-5847. 3. Mullin, Emily. \"How a ‘Living Drug’ Could Treat Autoimmune Disease.\" WIRED, 16 Sept 2022. 4. Assumes no dose-limiting toxicities are observed in the cohort, uninterrupted enrollment and no delays due to COVID-19 resurgence occur in the trial. 5. Pending clearance of CABA-201 IND by the FDA.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09186fdc-6c1a-45ba-9071-571154d68df7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.04,
        "y": 0.49
      },
      "kind": "list",
      "text": "CAART: Advancing clinical studies to increase CAART activity & explore additional indications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82b7615e-0106-4fdf-8086-f7e712f5b8c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.04,
        "y": 0.73
      },
      "kind": "list",
      "text": "Cash runway extended through 2Q24 with $96.8M at the end of 2Q22",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d43fc7a-ceb4-48ba-b745-b7a46fb89772",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.04,
        "y": 0.19
      },
      "kind": "list",
      "text": "CARTA: Newly-designed CABA-201 (4-1BB CD19-CAR T) on track for 1H23 IND submission",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d077e48f-4038-4c2a-b4ba-03682deb928c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.11
      },
      "kind": "title",
      "text": "Recent expansion into CD19-CAR T complements & leverages deep cell therapy experience in autoimmunity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95e63904-a6b6-4556-88cd-5e5a46b63b7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Cabaletta: Pursuing cures for a broad range of autoimmune diseases",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6ad2c56-0caa-4627-81b4-f6319ba67fdc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "c81c44af-c3eb-4b3a-8b93-23e62d58f13f",
      "evidence": "Recent expansion into CD19-CAR T complements & leverages deep cell therapy experience in autoimmunity",
      "confidence": 0.9
    },
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "319701e5-0e92-474d-8d01-b08babc2eda5",
      "evidence": "Recent expansion into CD19-CAR T complements & leverages deep cell therapy experience in autoimmunity",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 5,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "b163154e-4f70-4caa-bc21-030555bf0e22",
      "evidence": "Mission and solution slides",
      "position": 1,
      "objective": "Introduce Cabaletta Bio's mission and solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}